Financial Shenanigans

Financial Shenanigans — Zoetis Inc. (ZTS)

Zoetis's reported numbers broadly reconcile to economic reality, but three forensic signals warrant active monitoring in 2026: a 274M jump in receivables on flat revenue, a self-described Fiscal Year Alignment that pulled an estimated 2.5 to 3.5 percent of Q4 2025 International segment sales forward, and capital return that exceeded operating cash flow by 142 percent on the back of 3.85B in fresh long-term debt. There is no restatement, no auditor change, no disclosed material weakness, and 10-year operating cash flow conversion remains above 1.0x net income — clean evidence dampens the headline risk. The single data point that would most change this grade is the FY2026 first-half DSO trajectory; a return below 52 days would reclassify the receivables build as a timing artifact rather than a revenue-quality warning.

The Forensic Verdict

Grade: Watch (low end). Zoetis sits in the "elevated yellow, no red" zone. The accounting machinery is intact, the auditor (KPMG, long-tenured) has not flagged a material weakness, and 3-year operating-cash-flow conversion of 1.09x net income is what a high-quality, animal-health franchise should look like. What pulls the score above the "Clean" band is the combination of (i) a self-disclosed revenue-timing shift inside the Fiscal Year Alignment, (ii) FY2025 receivables growth running 18.5 percentage points ahead of revenue, (iii) capital return funded by new debt while cash declined, and (iv) two plaintiff-firm "investigations" announced in May 2026 that, while not regulatory action, signal that the market judged the Q1 2026 results as inconsistent with prior guidance. None of these are thesis breakers; together they cap conviction and warrant tighter underwriting of 1H 2026 working capital and segment disclosures.

13-Shenanigan Scorecard

Breeding Ground

The corporate plumbing is professional rather than promotional, but two structural items widen the fairway for stretched reporting: a dense web of non-GAAP adjustments that has grown a third layer (Fiscal Year Alignment), and a 92 percent at-risk CEO pay package whose long-term incentives are tied to "adjusted operational" performance.

The compensation lens is the one that matters most for shenanigan risk. CEO Kristin Peck's $17.0M target total direct compensation is 80 percent in long-term incentives, the bulk of which are performance share units tied to relative TSR versus the S&P 500 and to "adjusted operational" financial metrics — exactly the lens that benefits from a wider gap between GAAP and non-GAAP. That structure is industry-standard, but it places permanent pressure on adjusted earnings and operational growth. Combined with the multi-year beat-and-raise streak that ended only in Q1 2026, it raises the priors for revenue-timing scrutiny — which is precisely what the Fiscal Year Alignment delivered.

Earnings Quality

Reported earnings track economic earnings cleanly over time, but FY2025 introduced the first cross-statement tension in years: revenue growth slowed to 2.3 percent while receivables jumped 20.8 percent. The 18.5 percentage-point gap is the largest single-year delta in the company's post-IPO history. Management's FYA narrative — December 2025 customer orders delayed to January 2026, accelerated price increases pulling forward Q4 buying — provides a plausible explanation, but it also concedes that the cleanly reported Q4 was mechanically supported.

The chart isolates FY2025 as the only year in the visible series where receivables outpaced revenue by more than ~5 percentage points without a clear acquisition driver. FY2024 was the inverse — receivables grew 0.9 percent against 8.3 percent revenue growth, an unusually clean year. The two adjacent years together suggest a working capital see-saw rather than a steady deterioration, but the magnitude in 2025 is too large to ignore on its own.

Margin expansion is real and gradual rather than a step-up: gross margin moved from 66.6 percent in FY2017 to 71.8 percent in FY2025, operating margin from 32.2 percent to 37.5 percent. The lift is consistent with mix shift toward higher-margin companion-animal innovation (Apoquel, Cytopoint, Librela, Simparica Trio), and is supported by similar trends in segment revenue mix. There is no margin spike inconsistent with the volume trajectory. Net profit margin's lift from 26.0 percent (FY21) to 28.2 percent (FY25) outpaces operating margin slightly, helped by a lower interest cost base and tax efficiency rather than aggressive reserve releases.

The Non-GAAP wedge is narrow by pharma standards. FY2025's $174M gap is 6.5 percent of GAAP earnings — well below the 15-30 percent gaps typical of large-pharma adjusted measures. The composition is also defensible: $99M is purchase accounting amortization (a long-tail expense from past acquisitions where the underlying revenue was already booked), $2M is acquisition costs, and $73M is "certain significant items." The yellow flag is that "certain significant items" has now run at $27M to $84M for three consecutive years (restructuring + business process transformation + asset impairments + divestiture gain/loss), making the "nonrecurring" label increasingly difficult to defend.

Cash Flow Quality

Cash flow is the strongest defense in the file. Operating cash conversion has averaged 1.09 times net income across FY2023 through FY2025, and free cash flow conversion has averaged 83 percent — explained by a sustained capex program at 1.3x depreciation, not by any reclassification trick. No factoring, no supplier-finance program, no securitization is disclosed; the working-capital line items on the cash-flow statement reconcile back to balance-sheet deltas. The one structural pressure is on the capital-return side: FY2025 share buybacks of $3.24B plus dividends of $0.89B equal 142 percent of operating cash flow, financed by a $3.85B debt issuance and a step-up in net debt from $4.58B to $6.73B.

Across the 10-year window, CFO has tracked net income closely with two visible dips — FY2016 (a transition year after the Zoetis Bridge restructuring) and FY2022 (large inventory build during the pandemic recovery and channel restocking). Neither dip required a financing-style fix; both were absorbed organically.

The chart isolates the forensic question: did Zoetis use working capital to flatter CFO, or did working capital fight against CFO? Through FY2021-25 the answer is "fight against." Working capital was a $344M drain on CFO in FY2025 (receivables and inventory consumed more than payables sourced); it had been a $268M source in FY2024 (a one-off receivables collection year); and a $535M drain in FY2022 (the inventory-rebuild year). Across the cycle, CFO is not being subsidized by stretched payables or one-time benefits — the AP/COGS days (DPO at 63 days) is close to 5-year average, not stretched.

In FY2025, capital return ($4.12B) exceeded operating cash flow ($2.90B) by 42 percent. The shortfall was financed by $3.85B of new long-term debt — a deliberate balance-sheet decision rather than a forced one, but one that compresses optionality if 2026 earnings disappoint. It also raises the priors for adjusted-EPS support: with the diluted share count down 25 million (5.6 percent) year-over-year, EPS optics get a built-in lift that masks softening operational growth.

Metric Hygiene

Zoetis runs three layered non-GAAP frameworks — reported, operational (ex-FX), and organic operational (ex-FX and ex-recent-M&A) — and now overlays a fourth through the Fiscal Year Alignment recast. Each layer is defensible on its own; in combination they make peer comparisons fragile and reduce the marginal information value of any single metric.

Two metrics in that table moved in 2025 in ways that demand explanation. DSO drifted to 56.0 days, the highest level since FY2017 and a 4.3-day step-up from FY2024 — directly consistent with the disclosed delayed order processing at year-end. Net-debt-to-EBITDA jumped to 1.72 from 0.89 the prior year, driven entirely by the $3.85B debt issuance to fund buybacks rather than by EBITDA deterioration. Inventory days at 324 are stable but structurally high — normal for a biologics manufacturer that holds long-shelf-life vaccines, but worth flagging because it leaves Zoetis exposed to a multi-quarter inventory write-down risk if Librela or another franchise sees demand reset.

What to Underwrite Next

Five items would meaningfully tighten the read on this name. They are listed in order of materiality.

1. DSO trajectory through Q2 2026. The single most useful data point. A return to sub-52 days confirms the FYA timing narrative and downgrades the receivables flag from yellow to green. A reading above 54 days at June 30 2026, with revenue tracking the lower half of the $9.68B-$9.96B guide, would reclassify FY2025 as channel-supported and downgrade the forensic score by 10 to 15 points.

2. Fiscal Year Alignment recast schedule. Investors should download the supplemental schedule for the recast 2024 and 2025 quarterly periods. The forensic test: how much of the implied $200-280M International segment uplift in Q4 2025 plus Q1 2026 represents true business growth versus calendar shift. Anything more than a 1 percentage-point gap between recast organic operational growth and the previously reported number would warrant a discussion with IR.

3. Recurring "certain significant items" charges. Three consecutive years of $27-84M restructuring/transformation costs are no longer occasional. Investors should treat $30-50M of "significant items" as a recurring operating expense and rebase adjusted earnings accordingly. This narrows the bull case for adjusted EPS by roughly $0.07-0.11 per share on a steady-state basis.

4. Librela revenue and adverse-event monitoring. Librela is a top-five product and the source of the most concrete operational pressure visible in Q1 2026 (US companion-animal sales -11 percent). The FDA label update for adverse events is disclosed; the forensic question is whether the company has accrued any product-liability reserves. Note 18 (Commitments and Contingencies) is the file to read; any new reserve build would be a yellow flag for both earnings quality and risk.

5. Capital-allocation discipline. FY2025 buybacks at 142 percent of CFO funded by new debt represents the largest capital-return-to-CFO ratio in company history. If the FY2026 guidance midpoint holds, net leverage of ~1.7x is fine; if guidance is cut again, the buyback pace becomes a liquidity question.

The bottom line. The accounting risk at Zoetis is a valuation haircut, not a thesis breaker. The right way to use this report is to (i) discount FY2025 reported growth by approximately 1 percentage point for the FYA pull-forward, (ii) add roughly $50M of recurring "significant items" back into the steady-state cost base when modelling adjusted earnings, (iii) treat any FY2026 DSO above 54 days as a reason to fade the multiple, and (iv) remain alert to the plaintiff-firm investigations as a potential governance overhang rather than a confirmed misstatement. None of this changes the underlying franchise quality; all of it argues for tighter position sizing until the 1H 2026 disclosure clears the receivables question.